Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate
2. 5-bromo-6-(imidazolidinylideneamino)quinoxaline
3. 5-bromo-6-(imidazolin-2-ylamino)quinoxaline
4. Agn 190342
5. Agn-190342
6. Agn190342
7. Alphagan
8. Alphagan P
9. Brimonidine
10. Brimonidine Purite
11. Brimonidine Tartrate (1:1)
12. Brimonidine Tartrate (1:1), (s-(r*,r*))-isomer
13. Brimonidine Tartrate, (r-(r*,r*))-isomer
14. Bromoxidine
15. Mirvaso
16. Ratio Brimonidine
17. Ratio-brimonidine
18. Sanrosa
19. Uk 14,304
20. Uk 14,304 18
21. Uk 14,304-18
22. Uk 14,30418
23. Uk 14,308
24. Uk 14304
25. Uk 14308
26. Uk-14,304-18
27. Uk-14,308
28. Uk-14304
29. Uk14,30418
30. Uk14,308
31. Uk14304
1. 70359-46-5
2. Alphagan
3. Brimonidine Tartarate
4. Brimonidine L-tartrate
5. Lumify
6. Brimonidinne Tartrate
7. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine (2r,3r)-2,3-dihydroxysuccinate
8. Mirvaso
9. 4s9cl2dy2h
10. Agn 190342-lf
11. Brimonidine D-tartarate
12. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(2r,3r)-2,3-dihydroxybutanedioic Acid
13. Uk-14304-18
14. Qoliana
15. Agn-190342-lf
16. Bromoxidine Tartrate
17. (5-bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate
18. Brimonidine Purite
19. Brimonidine Tartrate [usan]
20. (2r,3r)-2,3-dihydroxybutanedioic Acid; 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine
21. 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
22. 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1)
23. 59803-99-5
24. Ocu300
25. Unii-4s9cl2dy2h
26. Ocu-300
27. Agn-190342lf
28. Alphagan-p
29. Cd-07805
30. Agn 190342lf
31. Brimonidine Tartrate [usan:jan]
32. N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine;(2r,3r)-2,3-dihydroxybutanedioic Acid
33. Alphagan (tn)
34. 304 Tartrate
35. Uk-1430418
36. 5-bromo-n-
37. Uk14304 Tartrate
38. Agn190342 Tartrate
39. Uk 14304 (tartrate)
40. Agn190342 (tartrate)
41. Uk 14,304 (tartrate)
42. Schembl265607
43. Chembl1200389
44. Ex-a5415a
45. Hy-b0659a
46. Dtxsid70911371
47. Brimonidine Tartrate (jan/usan)
48. Brimonidine Tartrate [jan]
49. Hms3715p18
50. Act08633
51. Brimonidine D-tartrate [mi]
52. Brimonidine Tartrate [vandf]
53. Brimonidine Tartrate [mart.]
54. Mfcd07773072
55. Brimonidine Tartrate [usp-rs]
56. Brimonidine Tartrate [who-dd]
57. Akos016845265
58. Ccg-221278
59. Cs-4496
60. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine(2r,3r)-2,3-dihydroxysuccinate
61. As-18083
62. Brimonidine Tartrate [orange Book]
63. Brimonidine Tartrate [ep Monograph]
64. Brimonidine Tartrate [usp Monograph]
65. Cd07805/47
66. Cd-07805/47
67. Combigan Component Brimonidine Tartrate
68. A19740
69. D02076
70. Simbrinza Component Brimonidine Tartrate
71. Brimonidine Tartrate Component Of Combigan
72. 359b465
73. Brimonidine Tartrate Component Of Simbrinza
74. (4,5-bihydro-1h-imidazol-2-yl)quinoxalin-6-amine L-tartrate
75. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl) Quinoxalin-6-amine Tartrate
76. 109826-56-4
| Molecular Weight | 442.22 g/mol |
|---|---|
| Molecular Formula | C15H16BrN5O6 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 441.02840 g/mol |
| Monoisotopic Mass | 441.02840 g/mol |
| Topological Polar Surface Area | 177 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 442 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Brimonidine tartrate |
| Drug Label | Brimonidine Tartrate Ophthalmic Solution, 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6 (2-imidazolidinylideneamino) quinoxaline L-tartrate. It is a white to sligh... |
| Active Ingredient | Brimonidine tartrate |
| Dosage Form | Solution/drops; Solution |
| Route | ophthalmic; Ophthalmic |
| Strength | 0.2%; 0.1% |
| Market Status | Tentative Approval; Prescription |
| Company | Apotex; Bausch And Lomb; Alcon Pharms; Sandoz; Akorn |
| 2 of 2 | |
|---|---|
| Drug Name | Brimonidine tartrate |
| Drug Label | Brimonidine Tartrate Ophthalmic Solution, 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6 (2-imidazolidinylideneamino) quinoxaline L-tartrate. It is a white to sligh... |
| Active Ingredient | Brimonidine tartrate |
| Dosage Form | Solution/drops; Solution |
| Route | ophthalmic; Ophthalmic |
| Strength | 0.2%; 0.1% |
| Market Status | Tentative Approval; Prescription |
| Company | Apotex; Bausch And Lomb; Alcon Pharms; Sandoz; Akorn |
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
D11AX21
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Curia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Parenteral
Coating Systems & Additives
Direct Compression
Solubilizers
Chewable & Orodispersible Aids
Taste Masking
Controlled & Modified Release
Disintegrants & Superdisintegrants
Topical
Granulation
Co-Processed Excipients
Film Formers & Plasticizers
Thickeners and Stabilizers
Coloring Agents
Emulsifying Agents
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Brimonidine Tartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brimonidine Tartrate manufacturer or Brimonidine Tartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brimonidine Tartrate manufacturer or Brimonidine Tartrate supplier.
PharmaCompass also assists you with knowing the Brimonidine Tartrate API Price utilized in the formulation of products. Brimonidine Tartrate API Price is not always fixed or binding as the Brimonidine Tartrate Price is obtained through a variety of data sources. The Brimonidine Tartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A SIMBRINZA manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SIMBRINZA, including repackagers and relabelers. The FDA regulates SIMBRINZA manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SIMBRINZA API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of SIMBRINZA manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A SIMBRINZA supplier is an individual or a company that provides SIMBRINZA active pharmaceutical ingredient (API) or SIMBRINZA finished formulations upon request. The SIMBRINZA suppliers may include SIMBRINZA API manufacturers, exporters, distributors and traders.
click here to find a list of SIMBRINZA suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A SIMBRINZA DMF (Drug Master File) is a document detailing the whole manufacturing process of SIMBRINZA active pharmaceutical ingredient (API) in detail. Different forms of SIMBRINZA DMFs exist exist since differing nations have different regulations, such as SIMBRINZA USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A SIMBRINZA DMF submitted to regulatory agencies in the US is known as a USDMF. SIMBRINZA USDMF includes data on SIMBRINZA's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The SIMBRINZA USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of SIMBRINZA suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The SIMBRINZA Drug Master File in Japan (SIMBRINZA JDMF) empowers SIMBRINZA API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the SIMBRINZA JDMF during the approval evaluation for pharmaceutical products. At the time of SIMBRINZA JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of SIMBRINZA suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a SIMBRINZA Drug Master File in Korea (SIMBRINZA KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of SIMBRINZA. The MFDS reviews the SIMBRINZA KDMF as part of the drug registration process and uses the information provided in the SIMBRINZA KDMF to evaluate the safety and efficacy of the drug.
After submitting a SIMBRINZA KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their SIMBRINZA API can apply through the Korea Drug Master File (KDMF).
click here to find a list of SIMBRINZA suppliers with KDMF on PharmaCompass.
A SIMBRINZA CEP of the European Pharmacopoeia monograph is often referred to as a SIMBRINZA Certificate of Suitability (COS). The purpose of a SIMBRINZA CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of SIMBRINZA EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of SIMBRINZA to their clients by showing that a SIMBRINZA CEP has been issued for it. The manufacturer submits a SIMBRINZA CEP (COS) as part of the market authorization procedure, and it takes on the role of a SIMBRINZA CEP holder for the record. Additionally, the data presented in the SIMBRINZA CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the SIMBRINZA DMF.
A SIMBRINZA CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. SIMBRINZA CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of SIMBRINZA suppliers with CEP (COS) on PharmaCompass.
A SIMBRINZA written confirmation (SIMBRINZA WC) is an official document issued by a regulatory agency to a SIMBRINZA manufacturer, verifying that the manufacturing facility of a SIMBRINZA active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting SIMBRINZA APIs or SIMBRINZA finished pharmaceutical products to another nation, regulatory agencies frequently require a SIMBRINZA WC (written confirmation) as part of the regulatory process.
click here to find a list of SIMBRINZA suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing SIMBRINZA as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for SIMBRINZA API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture SIMBRINZA as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain SIMBRINZA and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a SIMBRINZA NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of SIMBRINZA suppliers with NDC on PharmaCompass.
SIMBRINZA Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of SIMBRINZA GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right SIMBRINZA GMP manufacturer or SIMBRINZA GMP API supplier for your needs.
A SIMBRINZA CoA (Certificate of Analysis) is a formal document that attests to SIMBRINZA's compliance with SIMBRINZA specifications and serves as a tool for batch-level quality control.
SIMBRINZA CoA mostly includes findings from lab analyses of a specific batch. For each SIMBRINZA CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
SIMBRINZA may be tested according to a variety of international standards, such as European Pharmacopoeia (SIMBRINZA EP), SIMBRINZA JP (Japanese Pharmacopeia) and the US Pharmacopoeia (SIMBRINZA USP).
